SBIR/STTR Research Award
ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
Award amount
$775,506Program and phase
SBIR · Phase IIAward year
2005Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NANOTHERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- GC2RFAZK8G64
- Solicitation number
- PHS2005-1
- Topic code
- Not reported
Research abstract
N/A
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
- GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
- Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine
- ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
- Technologies to Defeat Improvised Explosive Devices (IED’s)
Research funding history
14 SBIR/STTR records share this UEI (2000–2013). Reported award amounts total $7,175,575. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Aeronautics and Space Administration
Contractor profile
RESILIENCE GOVERNMENT SERVICES, INC.
Historical federal award activity, when published, is on that contractor profile. Matched by UEI only.
Agency intelligence
Department of Health and Human Services
NAICS intelligence
This classification comes from the contractor profile, not from the SBIR award record.